Login

4-Hydroxyisoleucine

CAT:
804-HY-N6858-01
Size:
5 mg
Price:
Ask
For price, please contact [email protected]
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
4-Hydroxyisoleucine - image 1

4-Hydroxyisoleucine

  • CAS Number: 781658-23-9
  • UNSPSC Description: 4-Hydroxyisoleucine is an orally active amino acid that can be isolated from fenugreek seeds. 4-Hydroxyisoleucine displays insulinotropic and antidiabetic properties[1].
  • Target Antigen: Others
  • Type: Natural Products
  • Related Pathways: Others
  • Applications: Metabolism-protein/nucleotide metabolism
  • Field of Research: Metabolic Disease
  • Assay Protocol: https://www.medchemexpress.com/4-hydroxyisoleucine.html
  • Purity: 98.0
  • Solubility: DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 100 mg/mL (ultrasonic)
  • Smiles: N[C@@H]([C@@H](C)C(O)C)C(O)=O
  • Molecular Weight: 147.17
  • References & Citations: [1]Haeri MR, et al. The effect of fenugreek 4-hydroxyisoleucine on liver function biomarkers and glucose in diabetic and fructose-fed rats. Phytother Res. 2009 Jan;23(1):61-4. |[2]Zhou C, et al. 4-Hydroxyisoleucine relieves inflammation through iRhom2-dependent pathway in co-cultured macrophages and adipocytes with LPS stimulation. BMC Complement Med Ther. 2020 Dec 9;20(1):373.|[3]Jaiswal N, et al. 4-Hydroxyisoleucine stimulates glucose uptake by increasing surface GLUT4 level in skeletal muscle cells via phosphatidylinositol-3-kinase-dependent pathway. Eur J Nutr. 2012 Oct;51(7):893-8.|[4]Yang J, et al. 4-Hydroxyisoleucine Alleviates Macrophage-Related Chronic Inflammation and Metabolic Syndrome in Mice Fed a High-Fat Diet. Front Pharmacol. 2021 Jan 21;11:606514.|[5]Haeri MR, et al. Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine of fenugreek (Trigonella foenum graecum) in streptozotocin-induced type I diabetic rats. Phytomedicine. 2012 May 15;19(7):571-4.
  • Shipping Conditions: Room Temperature
  • Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information: No Development Reported